IMV

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced that Canada's NCIC Clinical
Trials Group (NCIC CTG) will sponsor and conduct a randomized Phase II study of
Immunovaccine's cancer vaccine, DPX-Survivac, in patients with advanced ovarian
cancer. The study is designed to assess whether IMV's vaccine therapy can delay
or prevent cancer recurrence. 


The Phase II trial is a randomized, blinded, placebo-controlled study with
DPX-Survivac in combination with low dose oral cyclophosphamide as an immune
modulator. The study will enroll approximately 250 patients with ovarian cancer
at an estimated 20 clinical centers. The NCIC CTG is a Canadian-based academic
clinical trials cooperative group conducting large multi-center clinical trials
across Canada and internationally.


Patients in the trial will have undergone surgery and standard post-operative
chemotherapy. Patients will be randomized to two groups, one receiving the
combination vaccine therapy and another receiving a placebo vaccine and
cyclophosphamide. Immune responses and disease-related biomarkers including
CA125 will be measured for correlative analyses. The results may guide further
development of DPX-Survivac. 


"NCIC CTG's decision to become actively involved in the development of our
cancer vaccine validates the approach we have been pursuing for the therapy of
ovarian cancer," said John Trizzino, CEO of Immunovaccine. "Directing the bulk
of the resources required to complete this study to NCIC CTG will help us
realize our ultimate goal, to bring advanced science to patients in need." 


Earlier this year, Immunovaccine published positive results from the Company's
Phase I clinical trial of DPX-Survivac. The data showed that all 18 patients who
had received DPX-Survivac in combination with cyclophosphamide produced targeted
immune responses and that the majority of patients in one cohort of the study
were strong responders who presented sustained circulating specific T cells (CD8
T cells) in their blood. 


The presence of circulating CD8 T cells is thought to be critical in treating
cancer because they are implicated in identifying and eradicating residual
cancer cells. Controlling or eliminating these escaped cells may be one way of
delaying or preventing recurrence of the cancer. 


The Phase I trial demonstrated that the vaccine had no systemic side effects or
dose-limiting toxicities. 


DPX-Survivac is among a class of immunotherapeutic treatments that have
attracted widespread interest in recent months. Bristol-Myers Squibb Company and
Merck & Co Inc. both announced in May that immunotherapeutic drugs they are
developing can dramatically influence the course of disease in cancer patients.
(View announcements: BMS and Merck.) 


As the incidence of cancer rises world-wide, researchers have been seeking ways
to reprogram a patient's own immune system to fight the disease and prolong
life. The results of the Bristol-Myers and Merck trials provide a leap forward
in immunotherapy. DPX-Survivac is an immunotherapeutic that is intended to teach
the immune system to recognize and kill cells displaying the survivin signature.
Survivin is present in many different types of cancer, including breast, colon
and melanoma among others. 


Ovarian cancer accounts for more deaths than any other gynecologic cancer.
Symptoms do not occur until it is in the later stages of the disease, reducing
the chance for successful treatment and remission. It kills more than 100,000
women annually around the world. Improved surgical techniques have helped to
reduce the rate of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than 4 years. 


The agreement between NCIC CTG and Immunovaccine will provide a framework for
the NCIC CTG to sponsor the randomized Phase II trial and assume responsibility
for conducting the trial in accordance with good clinical practice. The Company
is in discussion with potential co-development partners to support the NCIC
CTG-sponsored trial. 


"The NCIC CTG is recognized for its effectiveness in conducting large
international clinical trials," Trizzino said. "By working with the NCIC CTG, we
are able to advance our breakthrough science in an efficient and cost effective
manner." 


The trial is expected to get underway in 2014 with results in 2017.

About the NCIC Clinical Trials Group

The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials
cooperative group that conducts Phase I-III trials testing anti-cancer and
supportive therapies across Canada and internationally. It is a national
research program of the Canadian Cancer Society. The NCIC CTG's Central Office
is located at Queen's University in Kingston, Ontario, Canada. The Group is
committed to assessing all modalities of therapy for a spectrum of cancer types.
More than 60 member institutions, from major cancer centres to community
hospitals, enroll patients in NCIC Clinical Trials Group studies. Connect at
http://www.ctg.queensu.ca/.


About DPX-Survivac 

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in multiple cancer types in addition to ovarian cancer, including
breast, colon and lung cancers. Survivin plays an essential role in antagonizing
apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to
various anti-cancer therapies. Survivin is also a prognostic factor for many
cancers and it is found in a higher percentage of tumors than other TAA's.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
and specifically search for and destroy tumor cells. Survivin-specific T cells
have been shown to target and kill survivin-expressing cancer cells while
sparing normal cells.


About DepoVax(TM) 

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax(TM) platform possesses impressive flexibility,
allowing it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine 

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

(TSXV:IMV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024